Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.

In 30 seconds

This phase III randomized controlled trial evaluated the efficacy and safety of icotrokinra in 1505 adults with moderate-to-severe plaque psoriasis. Results showed that 70-75% of participants achieved clear or almost clear skin (IGA 0/1, PASI 90) at week 52, with durable responses observed. The safety profile was comparable to placebo, with no new safety signals identified.

Key findings

• Approximately 70-75% of participants achieved clear/almost clear skin (IGA 0/1, PASI 90) at week 52.
• Around 85-90% of those achieving clear/almost clear skin at week 16 maintained their response at week 52.
• Participants transitioning from placebo or deucravacitinib to icotrokinra had comparable response rates to those initially randomized to icotrokinra.
• The adverse event profile was similar to placebo through week 16 and lower than deucravacitinib through week 24.

Why it matters

The findings support icotrokinra as an effective systemic therapy for long-term management of moderate-to-severe plaque psoriasis, offering a convenient oral option with a favorable safety profile.